Product Pipeline

We have multiple and diverse cancer immunotherapies in our pipeline. These are in clinical and preclinical development directed against a range of cancer targets that have been identified and validated by Immatics’ proprietary XPRESIDENT® technology platform.

 

Stage

Partners

  • Discovery
  • Lead
  • CMC
  • Phase I/II
IMA201
IMA202
IMA203
In collaboration with
IMA300/301
Bispecific TCR/BiTE®
Multiple Programs
Bispecific mAb
Multiple Programs
Immunotherapies
Multiple Programs